论文部分内容阅读
目的探讨亚砷酸同步联合三维适形放射治疗原发性肝癌的临床疗效。方法本院2005年5月至2008年4月经临床、化验及影像学明确诊断不能手术的原发性肝癌患者35例,同步接受亚砷酸与三维适形放射治疗,术后3个月随访观察临床症状、实验室及影像学等指标变化情况。结果客观有效率(CR+PR)为42.8%,获益率(CR+PR+SD)为71.4%,;甲胎蛋白(AFP)下降率为84.3%,腹痛症状在3个月内基本缓解,缓解率为88.5%,主要副作用为发热、肝功能损害、血液学毒性及胃肠道反应。结论亚砷酸同步联合三维适形放射治疗原发性肝癌近期临床疗效可靠、无创、安全,能提高患者生存质量。
Objective To investigate the clinical efficacy of arsenious acid combined with three-dimensional conformal radiotherapy in the treatment of primary liver cancer. Methods From May 2005 to April 2008, 35 patients with primary hepatocellular carcinoma (HCC) who had inoperable surgery were diagnosed by clinical, laboratory and imaging studies. The patients were simultaneously treated with arsenic trioxide and three-dimensional conformal radiotherapy and were followed up for 3 months Clinical symptoms, laboratory and imaging changes and other indicators. Results The objective effective rate (CR + PR) was 42.8%, the rate of benefit (CR + PR + SD) was 71.4%, the rate of decline of AFP was 84.3%, and the symptoms of abdominal pain were basically relieved within 3 months The response rate was 88.5%. The main side effects were fever, liver damage, hematologic toxicity and gastrointestinal reactions. Conclusion Arsenious acid combined with three-dimensional conformal radiation therapy for the treatment of primary liver cancer in recent clinical efficacy reliable, noninvasive, safe, can improve the quality of life of patients.